Kiromic Biopharma, Inc.
CIK 0001792581
Revenue (TTM)
$0
FY Feb 2025
Net Income (TTM)
−$24.6M
−28.4% YoY
FY Feb 2025
EPS Diluted (TTM)
−$11.91
+80.5% YoY
FY Feb 2025
Gross Margin
—
FY Feb 2025
Operating Margin
—
FY Feb 2025
Net Margin
—
FY Feb 2025
Free Cash Flow (TTM)
−$23M
FY Feb 2025
Cash
$1.14M
FY Feb 2025
Total Debt
$192K
FY Feb 2025
Shares Outstanding
1.53M sh
FY Feb 2025
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.